<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740555</url>
  </required_header>
  <id_info>
    <org_study_id>HNC042-101</org_study_id>
    <nct_id>NCT03740555</nct_id>
  </id_info>
  <brief_title>A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single and Multiple Ascending Doses (SAD/MAD) Study Following Intravenous Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of HNC042.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Henovcom Bioscience Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Henovcom Bioscience Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this First-in-Human study is to evaluate the safety , tolerability and
      pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to
      placebo. Also, the safety , tolerability and pharmacokinetics of multiple ascending of HNC042
      given to healthy subjects daily for 7 days compared to placebo , will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2018</start_date>
  <completion_date type="Actual">July 19, 2019</completion_date>
  <primary_completion_date type="Actual">July 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Between screening and 7 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after a single and multiple intravenous dose in healthy subjects in terms of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal laboratory</measure>
    <time_frame>Between screening and 7days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after single and multiple intravenous dose in healthy subjects in terms of abnormal laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram</measure>
    <time_frame>Between screening and 7 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after a single and multiple intravenous dose in healthy subjects in terms of abnormal electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examination</measure>
    <time_frame>Between screening and 7 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after a single and multiple intravenous dose in healthy subjects in terms of abnormal physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal vital signs</measure>
    <time_frame>Between screening and 7 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after a single and multiple intravenous dose in healthy subjects in terms of abnormal vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The amount of HNC042 in plasma</measure>
    <time_frame>Between Day 1 predose and 24 hours after the (last) dose</time_frame>
    <description>To characterize the amount of HNC042 in plasma over time - pharmacokinetics (PK) - after a single and multiple intravenous dose in healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of HNC042 in urine</measure>
    <time_frame>Between Day 1 predose and 24 hours after the (last) dose</time_frame>
    <description>To characterize the amount of HNC042 in urine over time - pharmacokinetics (PK) - after a single and multiple intravenous dose in healthy subjects</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HNC042 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HNC042,freeze-dried powder,single ascending doses Single dose,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single ascending doses , Intravenous route Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HNC042 multiple ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HNC042,freeze-dried powder,multiple ascending doses, Intravenous route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, multiple ascending doses</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, multiple ascending doses, Intravenous route,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HNC042 single dose</intervention_name>
    <description>HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg</description>
    <arm_group_label>HNC042 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single dose</intervention_name>
    <description>Placebo single ascending doses , Intravenous route Single dose, matching placebo</description>
    <arm_group_label>Placebo single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HNC042 multiple ascending doses</intervention_name>
    <description>HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg</description>
    <arm_group_label>HNC042 multiple ascending doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo multiple ascending doses</intervention_name>
    <description>Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo</description>
    <arm_group_label>Placebo, multiple ascending doses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer, age 18-56 years

          -  BMI between 18-34 kg/m2,and body weight not less than 50.0kg.

        Exclusion Criteria:

          -  Any condition that might interfere with the procedures or tests in this study

          -  Drug or alcohol abuse

          -  Smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Paolo B. DePetrillo</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

